Deep dissection of the antiviral immune profile of patients with COVID-19.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
16 12 2021
Historique:
received: 18 03 2021
accepted: 02 11 2021
entrez: 17 12 2021
pubmed: 18 12 2021
medline: 1 1 2022
Statut: epublish

Résumé

In light of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants potentially undermining humoral immunity, it is important to understand the fine specificity of the antiviral antibodies. We screened 20 COVID-19 patients for antibodies against 9 different SARS-CoV-2 proteins observing responses against the spike (S) proteins, the receptor-binding domain (RBD), and the nucleocapsid (N) protein which were of the IgG1 and IgG3 subtypes. Importantly, mutations which typically occur in the B.1.351 "South African" variant, significantly reduced the binding of anti-RBD antibodies. Nine of 20 patients were critically ill and were considered high-risk (HR). These patients showed significantly higher levels of transforming growth factor beta (TGF-β) and myeloid-derived suppressor cells (MDSC), and lower levels of CD4

Identifiants

pubmed: 34916602
doi: 10.1038/s42003-021-02852-1
pii: 10.1038/s42003-021-02852-1
pmc: PMC8677724
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0
Coronavirus Nucleocapsid Proteins 0
Immunoglobulin G 0
Spike Glycoprotein, Coronavirus 0
Viral Proteins 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1389

Informations de copyright

© 2021. The Author(s).

Références

Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Gen Virol. 2002 Sep;83(Pt 9):2091-2108
pubmed: 12185262
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Int J Biol Sci. 2020 Apr 21;16(11):1954-1955
pubmed: 32398962
Eur J Immunol. 2020 Dec;50(12):2013-2024
pubmed: 33080068
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell. 2021 Mar 4;184(5):1171-1187.e20
pubmed: 33621484
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Chest. 2020 Jul;158(1):97-105
pubmed: 32304772
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cell Death Dis. 2020 Oct 27;11(10):921
pubmed: 33110074
Nat Commun. 2021 Mar 30;12(1):1961
pubmed: 33785765
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Nature. 2021 Mar;591(7848):124-130
pubmed: 33494096
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Front Immunol. 2020 Sep 30;11:582010
pubmed: 33117392
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2021 Apr 22;384(16):1576-1577
pubmed: 33596348
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Med Virol. 2020 Oct;92(10):1735-1738
pubmed: 32243608
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
Leukemia. 2020 Jan;34(1):317-321
pubmed: 31409922
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Blood Adv. 2020 Oct 13;4(19):4864-4868
pubmed: 33031540
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Cell Death Differ. 2020 Nov;27(11):3196-3207
pubmed: 32514047
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Sci Rep. 2020 Nov 26;10(1):20731
pubmed: 33244144
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Eur J Immunol. 2020 Dec;50(12):1998-2012
pubmed: 33073359
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Nat Commun. 2020 Nov 27;11(1):6044
pubmed: 33247152
Trends Immunol. 2011 Jan;32(1):19-25
pubmed: 21067974

Auteurs

Djordje Atanackovic (D)

Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA. datanackovic@som.umaryland.edu.
Department of Microbiology and Immunology, University of Maryland, Baltimore, MD, USA. datanackovic@som.umaryland.edu.

Stephanie V Avila (SV)

Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Forat Lutfi (F)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Diego de Miguel-Perez (D)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Xiaoxuan Fan (X)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Gabriela Sanchez-Petitto (G)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Erica Vander Mause (E)

Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Jonathan Siglin (J)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

John Baddley (J)

Division of Infectious Diseases, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Heather D Mannuel (HD)

Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Baltimore Veterans Affairs Medical Center, Baltimore, MD, USA.

Hanan Alkhaldi (H)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Kim G Hankey (KG)

Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Rena Lapidus (R)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Michael Kleinberg (M)

Division of Infectious Diseases, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Joseph Rabin (J)

R. Adams Cowley Shock Trauma Center, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.

Carl Shanholtz (C)

Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.

Christian Rolfo (C)

University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Aaron P Rapoport (AP)

Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Saurabh Dahiya (S)

Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.

Tim Luetkens (T)

Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Department of Microbiology and Immunology, University of Maryland, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH